CLINICAL_TRIALS
trial_result
· 2022-02-04
Clinical Trial Update: Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections [Phase 3]
Summary
Phase 3 study of oral oteseconazole for recurrent vulvovaginal candidiasis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mycovia Pharmaceuticals Inc. | Conditions: Recurrent Vulvovaginal Candidiasis | Phase 3 | Status: COMPLETED | Results posted: 2022-02-04